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Disruption of the Sarcoglycan±Sarcospan Complex
in Vascular Smooth Muscle: A Novel Mechanism
for Cardiomyopathy and Muscular Dystrophy
in Duchenne and Becker muscular dystrophy patients
(DMD/BMD) and can cause X-linked dilated cardiomy-
opathy (Towbin, 1998). Mutations in the genes for the
sarcoglycans, a subcomplex of transmembrane pro-
teins within the DGC, are responsible for limb girdle
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dence is accumulating that the DGC plays a critical5Department of Anatomy and Cell Biology
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The DGC confers a structural link between laminin-2
in the extracellular matrix and the F-actin cytoskeleton
(Ervasti and Campbell, 1993) and is thought to protectSummary
muscle cells from contraction-induced damage (Petrof
et al., 1993). The tetrameric unit of a-, b-, g-, andTo investigate mechanisms in the pathogenesis of car-
d-sarcoglycan is a group of single pass transmembranediomyopathy associated with mutations of the dys-
glycoproteins. Interestingly, a- and g-sarcoglycan ex-trophin±glycoprotein complex, we analyzed genetically
pression is restricted to skeletal and cardiac muscleengineered mice deficient for either a-sarcoglycan
tissue (Roberds et al., 1994; Noguchi et al., 1995). In(Sgca) or d-sarcoglycan (Sgcd). We found that only
contrast, b-, d-, and e-sarcoglycan (an a-sarcoglycanSgcd null mice developed cardiomyopathy with focal
homolog), along with sarcospan, are additionally ex-areas of necrosis as the histological hallmark in car-
pressed in smooth muscle cells (Straub et al., 1999). Indiac and skeletal muscle. Absence of the sarcoglycan±
order to test the hypothesis that the diversity in tissuesarcospan (SG-SSPN) complex in skeletal and cardiac
expression may be responsible for different pathoge-membranes was observed in both animal models. Loss
netic mechanisms and distinct clinical phenotypes, we
of vascular smooth muscle SG-SSPN complex was
engineered Sgcd null mice deficient for d-sarcoglycan
only detected in Sgcd null mice and associated with (expressed in skeletal, cardiac, and smooth muscle) and
irregularities of the coronary vasculature. Administra- compared them to Sgca null mice deficient for a-sarco-
tion of a vascular smooth muscle relaxant prevented glycan (only expressed in skeletal and cardiac muscle).
onset of myocardial necrosis. Our data indicate that Sgca null mice have recently been reported to display
disruption of the SG-SSPN complex in vascular smooth a progressive muscular dystrophy (Duclos et al., 1998).
muscle perturbs vascular function, which initiates car- The primary absence of a-sarcoglycan was accompa-
diomyopathy and exacerbates muscular dystrophy. nied by the concomitant loss of b-, g-, and d-sarcoglycan
and sarcospan in skeletal and cardiac muscle fibers, a
phenomenon that is also observed in human forms of
Introduction sarcoglycanopathies (Lim and Campbell, 1998). Inter-
estingly, although the sarcoglycan±sarcospan (SG-SSPN)
Dilated cardiomyopathy is a multifactorial disease that complex was absent from the cardiac muscle mem-
includes both inherited and acquired forms of cardiomy- brane, no morphological signs of cardiomyopathy were
opathy. Inherited cardiomyopathy in humans can be as- observed (Duclos et al., 1998). In contrast, Sgcd null
sociated with genetic defects occurring in components mice exhibited a remarkably different phenotype. These
of the dystrophin±glycoprotein complex (DGC) (Towbin, mice displayed a severe muscular dystrophy with large
1998). In both skeletal and cardiac muscle, the DGC areas of necrosis as a predominant characteristic fea-
consists of dystrophin, the syntrophins, a- and b-dys- ture similar to alterations observed in tissue infarcts. In
troglycan (a-, b-DG), the sarcoglycans (a-, b-, g-, d-SG), addition, a severe cardiomyopathy developed after the
and sarcospan (SSPN) (for review, see Crosbie et al., age of 3 months. The predominant pathological features
1997; Straub and Campbell, 1997). Mutations in the dys- were focal multicellular myocytolytic lesions sharply
trophin gene lead to a high incidence of cardiomyopathy demarcated from surrounding normal-appearing myo-
cytes. Another striking difference between Sgca and
Sgcd null mice was the disruption of the SG-SSPN com-6To whom correspondence should be addressed (e-mail: kevin-
plex in vascular smooth muscle (e.g., coronary arteries)campbell@uiowa.edu).
7Both authors contributed equally to this work. of Sgcd null mice and preservation of this complex in
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Figure 1. Targeted Disruption of the Mouse Sgcd Gene
(A) Restriction map of the 59 portion of the Sgcd gene, showing wild-type allele (top), targeting vector (middle), and the predicted targeted
allele following homologous recombination (bottom). The position of the neo and tk cassettes, probes A and B, for Southern analyses, and
the primers used for PCR-based genotyping (→) are indicated.
(B) DNA from ES colonies surviving double selection was restricted by EcoRI or BamHI/XhoI and probed by Southern blot with probes A and
B, respectively. The replacement of exon 2 by the neo cassette yields a new 8.8 kb fragment, which hybridized with probe A in addition to
the 7 kb wild-type fragment. As a consequence of the XhoI site introduced by the neo cassette, probe B hybridizes with a 5 kb fragment and
the 7.5 kb wild-type allele.
(C) PCR analysis of tail DNA purified from wild-type (1/1), heterozygous (1/2), and Sgcd null (2/2) mice. The wild-type and targeted alleles
produced PCR products of 600 bp and 700 bp, respectively.
(D) Northern analysis of RNA extracted from muscle of wild-type (1/1), heterozygous (1/2), and Sgcd null (2/2) mice. A cDNA probe for the
complete Sgcd gene coding sequence detected a 9 kb transcript in mice of all three genotypes. In contrast, hybridization with a probe
corresponding to exon 2 showed the 9 kb transcript only in wild-type (1/1) and heterozygous (1/2) mice.
(E) Immunoblot analysis of skeletal muscle membrane±enriched preparations using an affinity-purified polyclonal antibody against the N-terminal
(N) and C-terminal (C) peptide of d-sarcoglycan reveals protein expression in wild-type (1/1) but not Sgcd null (2/2) mice.
the Sgca null mice. In vivo perfusion of coronary arteries acids of the intracellular domain and the entire trans-
membrane domain (Figure 1A). Southern blot analysisrevealed vascular constrictions often associated with
pre- and poststenotic dilation and an overall decrease in of 370 neomycin-resistant embryonic stem (ES) colonies
revealed homologous recombination in seven indepen-vessel lumen size in Sgcd null mice. These abnormalities
preceded the onset of necrosis and were most pro- dent clones (Figure 1B). Two of these heterozygous
clones were then used to produce chimeric foundernounced at the time of ongoing necrosis. Treadmill exer-
cise±induced stress triggered the onset of multiple focal mice. Heterozygous mice from the F1 generation were
myocardial lesions in Sgcd null mice. Administration of crossed to obtain Sgcd null mice, and the offspring were
Nicorandil, a vascular smooth muscle relaxant, pre- tested for exon 2 deletion by Southern blot and PCR
vented the development of acute myocardial necrosis analysis (Figure 1C). The number of homozygous mutant
in Sgcd null mice. These findings suggest a novel patho- offspring obtained was the expected 25%, based on
genetic mechanism whereby disruption of the SG-SSPN Mendelian inheritance. Northern blot analysis, using the
complex in vascular smooth muscle causes functional complete cDNA coding sequence of d-sarcoglycan gene
disturbance of the vasculature, which in turn leads to as a probe, revealed a transcript of 9 kb in the skeletal
the development of a severe cardiomyopathy and exac- muscle of wild-type, heterozygous, and homozygous
erbation of muscular dystrophy in Sgcd null mice. Sgcd null mice (Figure 1D). An additional hybridization
with a probe specific for exon 2 showed the 9 kb tran-
Results script only in the wild-type and heterozygous mice, not
in the mutants (Figure 1D). RT-PCR analysis performed
with a forward primer in exon 1 and a reverse primer inGeneration of the Sgcd Null Mice
In order to create Sgcd null mice, a targeting vector was exon 5 revealed a PCR product representing the normal
transcript (600 bp) in wild-type and heterozygous micedesigned to replace exon 2, which encodes 63 amino
Sarcoglycan±Sarcospan Complex and Cardiomyopathy
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Figure 2. Histological Analysis of Sgcd-Deficient Thigh, Calf, and Diaphragm Muscles
Severe dystrophic changes were evident in skeletal muscle at all three sites from a very early age. Shown are calf (A and C), thigh (B and D),
and diaphragm (E) from a 1-month-old Sgcd null mouse. All but the upper right and lower right corners of the calf muscle in (A) are at various
stages of acute necrosis or regeneration. The pale central area of (C) is a higher magnification of an area of acute necrosis similar to that
outlined by the black box in (A). Similarly, large areas of necrosis and regeneration in the thigh are shown in (B); the regenerating area within
the black box is shown at a higher magnification in (D), where a large percentage of myocytes contain centrally placed nuclei. Regions of full
thickness necrosis or regeneration were seen in the diaphragms of these mice (see the purple region on the left of [E]). Chronic dystrophic
changes accumulated with age in all of these same muscle groups. Central nucleation, endomysial fibrosis, atrophy, hypertrophy, and fatty
infiltration are shown in the diaphragm from a 1-month-old mouse (F). All sections were stained with hematoxylin and eosin. Scale bars
represent 1 mm (A), 400 mm (B), 150 mm (C and D), 350 mm (E), and 100 mm (F), respectively.
and an additional PCR product (400 bp) in heterozygous Sgcd Null Mice Exhibit a Severe
Muscular Dystrophyand mutant mice (data not shown). Sequencing of this
PCR product suggested that alternative splicing oc- In order to examine the effect of targeted disruption of
the d-sarcoglycan gene on skeletal muscle morphology,curred between exon 1 and exon 3 of the d-sarcoglycan
gene. In this case, an open reading frame from exon 3 to hematoxylin and eosin (H&E)-stained sections of the
calf, thigh, and diaphragm muscles were evaluated inexon 8 would be maintained. Translation of this smaller
transcript would produce a 218 aa protein lacking the wild-type (n 5 8), Sgca and Sgcd heterozygous (n 5
26), and Sgcd null mice (n 5 26) between the ages of 2entire transmembrane domain and part of the N termi-
nus. However, no protein was detected in the skeletal weeks and 6 months. Sgcd heterozygous mice did not
show any morphological abnormalities. Interestingly,and cardiac muscle fibers of the Sgcd null mice by West-
ern blot of total homogenates and KCl-washed micro- the skeletal muscle of the Sgcd null mice, even in the
very young animals (n 5 8), showed extensive pathologi-somes by using antibodies directed against the C-termi-
nal or N-terminal portion of d-sarcoglycan (Figure 1E). cal alterations. The predominant feature was consistent
with various stages of skeletal muscle necrosis or regen-Immunohistochemical analysis of skeletal (data not
shown) and cardiac muscle revealed complete absence eration similar to pathological alterations observed in
tissue infarcts (Figures 2A±2D). Large regions of necro-of d-sarcoglycan with the concomitant loss of the SG-
SSPN complex (Figure 5). Overall, the Sgcd null mice sis/regeneration were observed in calf and thigh mus-
cles of mice at all ages. Severe necrotic lesions in theare fertile, and females can bear at least two litters.
Although a controlled aging study is in progress, prelimi- diaphragm were predominantly seen in younger animals
at 1 month of age (Figures 2E and 2F). Similar findingsnary data indicate an increased number of spontaneous
deaths in Sgcd null mice at around 6 months of age. were observed in a second founder from another cell
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Figure 3. Histological Analysis of Sgcd-Defi-
cient Hearts
At the age of 5 months, numerous well-cir-
cumscribed regions of myocardial necrosis
were observed; two such lesions are present
in (A), one in the papillary muscle within the
black box and one in the interventricular sep-
tum immediately across the ventricle from the
black box. A higher magnification of the papil-
lary muscle lesion is shown in (C). By 6
months of age, much more severe cardiomy-
opathy was present (B). Pathologic changes
now included fibrosis (scarring) and calcifica-
tion in addition to ongoing myocardial necro-
sis. These changes are more readily dis-
cernable in the higher magnification of the
papillary muscle (D) that is outlined by the
black box in (B). All sections were stained
with hematoxylin and eosin. Scale bars repre-
sent 1.5 mm (A and B), 75 mm (C), and 150
mm (D), respectively.
line of targeted ES cells. Based on the evaluation of evaluations of the myocardium of Sgca null mice (includ-
ing pregnant females) showed no pathological alter-200±1100 myofibers per muscle, 80%±100% of nonre-
generating myocytes contained internally placed nuclei ations besides minimal calcification in some of the older
animals (data not shown). No coronary vessel histopa-by the age of 1 month (n 5 4). In addition to the described
severe necrotic/regenerative lesions, a broad spectrum thology at the light microscopy level was observed.
In order to evaluate the impact of the morphologicalof other dystrophic changes was observed in older (.4
months) Sgcd-deficient muscle (n 5 18). These changes changes on electrophysiological function, we performed
ECG telemetry in wild-type (n 5 10), Sgca null (n 5 6),included endomysial fibrosis, fiber splitting, hypertro-
phy, dystrophic calcification, and fatty infiltration. Evalu- and Sgcd null (n 5 6) mice (Figure 4). Resting heart rates
were similar among the three different genotypes, asation of creatine kinase (CK) levels in Sgcd null mice
revealed a 15- to 20-fold elevation of CK as compared were PR intervals (a measure of AV nodal conduction).
No ventricular arrhythmias were seen in any of the mice.to wild-type mice.
Electrocardiographic characteristics were similar be-
tween wild-type and Sgca null mice. Ventricular excita-Sgcd Null Mice Display Severe Cardiomyopathy
In order to evaluate whether disruption of the d-sarcogly- tion (QRS amplitude and duration), however, was mark-
edly perturbed in the Sgcd null mice as compared withcan gene may cause cardiac abnormalities, we per-
formed H&E staining of transverse sections of hearts wild-type and Sgca null mice. The most striking difference
between the Sgcd null, wild-type, and Sgca null mice wasfrom wild-type (n 5 8) and Sgcd null mice between the
ages of 2 weeks and 6 months (n 5 26). From 2 weeks the dramatically smaller QRS amplitudes (n 5 3) consistent
with dispersion of depolarization through the ventricle.to 3 months of age (n 5 8), hearts from Sgcd null mice
were nearly normal, and only rare, small foci of necrosis Consistent with the idea that the fibrotic lesions detected
in Sgcd null mice underlie the abnormal activation, Sgcdwere seen. Myocardial tissue studied after 3 months of
age revealed more extensive alterations (n 5 18). Larger null mice (n 5 3) with less severe pathological findings
did not reveal significant ECG abnormalities.and more numerous foci of active cellular necrosis and
granular calcium deposits involving small groups of
myocytes were present (Figures 3A and 3C). These foci Disruption of the SG-SSPN Complex in the Smooth
Muscle of the Coronary Arteries in Sgcd Null Micewere sharply demarcated from surrounding tissue, which
appeared to be normal. The localization and extent of The characteristic histopathological abnormalities sug-
gested that alterations in vascular smooth muscle mightpathology predilection sites varied considerably from
animal to animal. In some hearts, subendocardial re- be responsible for these findings. Recent biochemical
studies (Straub et al., 1999) suggest that the composi-gions were predominantly affected (Figure 3A), whereas
in others, pathological changes in the outer two-thirds tion of SG-SSPN complex in smooth muscle is distinct
from that in skeletal and cardiac muscle. Consequently,of the free walls of both ventricles were observed (Figure
3B). In older animals (5±6 months; n 5 14), active myo- we performed immunohistochemical analysis of compo-
nents of the DGC in cardiac muscle fibers and smoothcardial necrosis was less evident, but various stages of
calcification and fibrosis were observed (Figures 3B and muscle cells of coronary arteries from wild-type, Sgca,
and Sgcd null mice (Figure 5). In wild-type mice, a-, b-,3D). Interestingly, female mice that had been pregnant
at least once (n 5 4) displayed more widespread and g-, d-, and e-sarcoglycan, sarcospan, and b-dystroglycan
were homogeneously expressed at the cardiac muscleadvanced cardiac alterations than age-matched virgin
females (n 5 4). In contrast, extensive histopathological fiber membranes. b-, d-, and e-sarcoglycan, sarcospan,
Sarcoglycan±Sarcospan Complex and Cardiomyopathy
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Figure 4. Comparison of Histopathology and ECG Telemetry in
Wild-Type, Sgca, and Sgcd Null Mice
H&E staining of cardiac cross sections of wild-type, Sgca, and Sgcd
null mice reveal cardiomyopathic changes only in Sgcd null mice.
The Sgcd-deficient heart shows severe dilation of the ventricle as
well as multiple areas of necrosis and fibrosis. Scale bar represents
1.5 mm. Lead II ECG recordings from conscious mice from three
genetic backgrounds (wild-type, Sgca, and Sgcd null mice) made
under identical conditions. In the upper row of ECGs, the horizontal
bar corresponds to 100 ms. ECGs in the lower row were enlarged
arbitrarily to illustrate QRS morphology.
and b-dystroglycan were also strongly expressed in the
smooth muscle cells of the coronary arteries. In contrast,
a- and g-sarcoglycan were not expressed in smooth
muscle cells of coronary arteries. In cardiac muscle fi-
bers of Sgca null mice, a-sarcoglycan was absent from
the sarcolemma, whereas d-sarcoglycan was absent
from the sarcolemma of Sgcd null mice. In addition,
there was a concomitant loss of a-, b-, g-, and d-sarco-
glycan. Sarcospan was absent from the sarcolemma of
both animal models. Interestingly, e-sarcoglycan was
absent from the sarcolemma of Sgcd null mice, in con-
Figure 5. Immunohistochemical Expression of the SG-SSPN Com-trast to wild-type and Sgca null mice. However, the most
plex in Cardiac Muscle and Smooth Muscle of Coronary Arteries inremarkable difference between the Sgca and the Wild-Type, Sgca, and Sgcd Null Mice
Sgcd null mice was observed in the expression of the
In wild-type mice, a-, b-, g-, d-, and e-sarcoglycan, sarcospan, and
SG-SSPN complex in the smooth muscle of coronary b-dystroglycan are strongly expressed in cardiac membranes. In
arteries. While b-, d-, and e-sarcoglycan, along with sar- contrast, b-, d-, e-sarcoglycan, sarcospan, and b-dystroglycan are
cospan, were still strongly expressed in the coronary expressed in smooth muscle cells of coronary arteries, while a- and
g-sarcoglycan are not. In Sgca and Sgcd null mice, a-, b-, g-, andarteries of the Sgca null mice, these proteins were com-
d-sarcoglycan, as well as sarcospan, are absent from cardiac mem-pletely absent in the smooth muscle cells of Sgcd null
branes, while b-dystroglycan is still present at comparable levelsmice. The same expression pattern was observed in
to normal controls. The expression pattern in smooth muscle, though,
smooth muscle cells of other blood vessels, for example, is strikingly different. In smooth muscle, b-, d-, and e-sarcoglycan and
the femoral artery (data not shown). Western blot analy- sarcospan are absent in coronary arteries of Sgcd null mice, while
sis of aortic tissue confirmed our immunohistochemical these proteins are still expressed in Sgca null mice. Note also the
absence of e-sarcoglycan at the sarcolemma of Sgcd null mice. Theobservation that the SG-SSPN complex is disrupted in
expression of b-dystroglycan is not altered in the smooth muscleSgcd null mice, while it is still preserved in aorta from
of Sgcd null mice. Staining with an antibody against smooth musclewild-type and Sgca null mice (data not shown). Taken
actin confirmed the presence of smooth muscle in the vasculature.together, these results indicate that targeted ablation
Scale bar represents 20 mm.
of the d-sarcoglycan gene leads to disruption of the SG-
SSPN complex in smooth muscle, whereas the complex
is preserved in smooth muscle cells of Sgca null mice.
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Figure 6. Perfusion of Coronary Artery Vas-
cular Bed
Transillumination of Microfil-perfused coro-
nary arteries in wild-type (upper panel) and
Sgca null mice (upper right panel) shows
smoothly tapered vessels without signs of
constriction and/or focal narrowing. In con-
trast, coronary vessels of Sgcd null mice
(lower panel) show multiple constrictions
(arrows) with pre- and poststenotic dilations
as well as narrow vessels with a serrated
rather than a smooth contour. Cleared tissue;
scale bar represents 40 mm.
Coronary Artery Vascular Irregularities and Sgcd null mice (n 5 42) for 40 min using a treadmill.
The exercised mice were studied at the age of 2±3in Sgcd Null Mice
months, a time where Sgcd null mice do not show anyIn order to demonstrate whether disruption of the SG-
overt signs of cardiac muscle necrosis but do have mi-SSPN complex in smooth muscle of coronary arteries
crovessel abnormalities, as revealed by our perfusionindeed leads to vascular perfusion abnormalities, we
studies. All mice were injected with Evans blue dye (EBD)used the Microfil perfusion technique in vivo. We per-
8 hr before the exercise, and assessment of EBD uptake,fused wild-type, Sgca null, and Sgcd null mice at the
as well as routine histopathology, was examined in theage of 2±6 months, and cleared sections of the heart
cardiac muscle. Interestingly, approximately one-thirdwere visualized using transillumination with low-power
of the Sgcd null mice died suddenly during the exercise,magnification. The coronary microvessels were distrib-
while no death occurred in Sgca null and wild-type mice.uted normally and were smoothly tapered in both wild-
The surviving Sgcd null mice were sacrificed 36±48 hrtype and Sgca null mice (Figure 6). Some animals
after exercise for histological assessment of cardiacshowed areas of focal vessel narrowing but never
muscle. All mice displayed multiple areas of EBD uptakeshowed any severe irregularities. In contrast, Sgcd null
corresponding to acute histopathological features of ne-mice displayed numerous areas of pronounced con-
crosis, as revealed by H&E staining (Figure 7). No signsstrictions. Pre- and poststenotic dilation as an appear-
of necrosis were detected in age-matched, nonexer-ance of microaneurysm was frequently associated with
cised Sgcd null or wild-type mice. Only a few singlethese constrictions (Figure 6). Extensive areas of focal
necrotic cells were observed in Sgca null mice (Figurevascular lumen narrowing and a generalized sparseness
7). Quantification of Evans blue staining after treadmillof perfusion were observed. Interestingly, although gen-
exercise revealed 13%±27% positive stained areas ineral perfusion was diminished in capillaries of Sgcd null
cardiac muscle sections of Sgcd null mice and less thanmice, no constrictions were observed. Quantification of
3% positive stained areas in Sgca null mice.vascular abnormalities in Sgcd null mice at different
Intraperitoneal administration of Nicorandil, a vascu-
ages was determined by calculating the mean numbers
lar smooth muscle relaxant, was able to prevent the
of abnormal vessels 6 SEM in ten nonadjacent micro- development of multiple myocardial ischemic lesions in
scopic fields at a magnification of 103. No lesions were all Sgcd null mice (n 5 20) studied (Figure 7). Microfil
detected in Sgca null and wild-type mice. Analysis of perfusion of coronary arteries in Sgcd null mice after
Sgcd null mice revealed irregularities in 2- (5 6 1.1), administration of Nicorandil revealed no evidence of
4- (11 6 1.5), and 6-month-old mice (4 6 0.9) (n 5 10 vascular constrictions and displayed smoothly tapered
in each age group). However, the most severe and abun- branches of the coronary vascular bed (Figure 7). Nicor-
dant abnormalities were observed at the age of 4 months, andil, at the dose given, did not lower the systemic blood
a time when acute necrosis was first observed in Sgcd pressure in Sgcd null mice (data not shown). In addition,
null mice. These results indicate that the disturbance no alteration of the general behavior during exercise or
of the vasculature precedes the onset of myocardial any cardiac muscle abnormalities were observed during
ischemic lesions. or after exercise of wild-type or Sgca null mice after
administration of Nicorandil.
Treadmill Exercise Initiates the Development
of Cardiac Muscle Necrosis Discussion
in Young Sgcd Null Mice
In order to test the hypothesis that the observed abnor- The present study reports that disruption of a sarcogly-
malities of the vasculature represent a dynamic hyper- can±sarcospan complex in vascular smooth muscle per-
reactivity of the vasculature, which may be triggered by turbs vascular function, which in turn initiates the devel-
opment of cardiomyopathy and exacerbates muscularstress, we exercised wild-type (n 5 20), Sgca (n 5 20),
Sarcoglycan±Sarcospan Complex and Cardiomyopathy
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Figure 7. Treadmill Exercise±Induced Myo-
cardial Necrosis Is Prevented by Administra-
tion of a Vascular Smooth Muscle Relaxant
Evaluation of Evans blue dye (EBD) uptake
and corresponding histopathological assess-
ment reveals no uptake of EBD in nonexer-
cised 2-month-old Sgcd null mice (upper
panel) and only a few positive EBD cardiomy-
ocytes in Sgca null exercised mice corre-
sponding to single cell necrosis (second
panel from top). In contrast, Sgcd null mice
display multiple areas of EBD uptake after
treadmill exercise, which correspond to acute
histopathological signs of necrosis (second
panel from bottom). Each asterisk represents
the corresponding area of EBD positive fi-
bers. Scale bar represents 500 mm. No EBD
uptake was observed in cardiac muscle of
2-month-old exercised Sgcd null mice after
intraperitoneal application of Nicorandil for 3
days prior to the exercise (lower left panel).
Scale bar represents 1.5 mm. Microfil perfu-
sion of Sgcd null mice after Nicorandil treat-
ment displayed no perfusion abnormalities of
the vasculature and a smoothly tapered ves-
sel bed (lower right panel). Note also the over-
all greater density of the vasculature. Scale
bar represents 40 mm.
dystrophy in Sgcd null mice. Cardiomyopathy is a com- and scarring of the cardiac muscle. Electrocardiography
revealed evidence of dispersion of electrical activationmon clinical phenotype of patients with certain forms
of LGMD. Interestingly, cardiac involvement has been in cardiomyopathic mice in a pattern roughly propor-
tional to the degree of fibrotic change in the left ventricle.described in patients with primary mutations of b-, g-,
and d-sarcoglycan (Nigro et al., 1996; Moreira et al., This is similar to that seen in patients with cardiomyopa-
thy and indicates that the structural alterations we ob-1998; Melacini et al., 1999; R. D. C. and T. Voit, unpub-
lished observations), while patients with mutations in served disrupt the wave front of depolarization in the
heart.the a-sarcoglycan gene (the most common form of sar-
coglycanopathies) only rarely display mild forms of car- The essential difference between Sgca and Sgcd null
mice was observed in the expression of the SG-SSPNdiomyopathy (Melacini et al., 1999).
In order to analyze the involvement of sarcoglycans complex in smooth muscle cells of the vasculature.
While in both mutants the expression of the SG-SSPNin the pathogenesis of cardiomyopathy and muscular
dystrophy, in particular with respect to the different tis- complex was reduced at the sarcolemma of skeletal and
cardiac muscle, the expression of the sarcoglycan±sue distribution, we analyzed Sgcd null mice and com-
pared them with the previously described Sgca null mice sarcospan complex in smooth muscle cells of the blood
vessels was disrupted only in the Sgcd null mice. These(Duclos et al., 1998). Morphological evaluation of Sgca-
deficient hearts revealed no histopathological signs of findings, together with the characteristic ischemic-like
lesions in cardiac and skeletal muscle of Sgcd null mice,cardiomyopathy, although the SG-SSPN complex was
absent in cardiac muscle membranes. These findings led us to hypothesize that vascular dysfunction may
have an essential impact on the development of cardio-are in accordance with the clinical data observed in
patients with primary mutations in the a-sarcoglycan myopathy and the severity of muscular dystrophy in
Sgcd null mice.gene, which also do not displayÐor display only mildlyÐ
cardiomyopathic phenotypes. Interestingly, Sgcd null In fact, Microfil in vivo perfusion of the coronary artery
vascular bed of Sgcd null mice revealed numerous ves-mice developed a severe cardiomyopathy with focal areas
of myocardial ischemic-like lesions as the characteristic sel segments with constrictions and focal luminal nar-
rowing. In contrast, smoothly tapered vessels and ahistopathological feature followed by fibrotic calcification
Cell
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greater density of small arteries without focal narrowing Sgcd null mice renders cardiomyocytes more suscepti-
ble to the vascular dysfunction. However, we did demon-were detected in wild-type and Sgca null mice, both
strate that the functional disturbance of the vasculatureshowing normal expression of the SG-SSPN complex
initiates ischemic myocardial necrosis. As mice age, thisin the vascular smooth muscle. The Microfil in vivo perfu-
damage develops into a severe cardiomyopathy.sion enabled us to study long segments of coronary
Recently, Hack and colleagues (1998) reported thatartery branches in three dimensions. Quantification of
mice deficient in g-sarcoglycan develop cardiomyopa-perfusion abnormalities in Sgcd null mice revealed that
thy. The authors described primarily fibrotic changes invessel irregularities are present even in young mice at
the ventricular wall. However, there was no report ofa stage without any overt signs of cardiac muscle necro-
initial acute necrotic areas in cardiac muscle, and thesis. Moreover, the most severe and abundant perfusion
authors suggested that the cardiomyopathy might beabnormalities were observed at the time of acute ongo-
secondary to dystrophic changes of the diaphragm. An-ing necrosis, suggesting that a certain degree of vascu-
other animal model, the BIO 14.6 cardiomyopathic ham-lar dysfunction may be required to reach an ischemic
ster, which has been shown to have a genomic deletionthreshold necessary to induce myocardial necrosis.
in the d-sarcoglycan gene (Sakamoto et al., 1999), dis-These data indicate that the lesions observed in Sgcd
plays cardiac abnormalities similar to the Sgcd null micenull mice are not an induced epiphenomenon caused
and associated with microvascular dysfunction (Factorby alterations of the cardiac muscle per se. We propose
et al., 1982). However, the skeletal muscle of the cardio-that increased vascular tone compromises blood supply
myopathic hamster is dystrophic but not as severe asin a diffuse manner, leading to focal ischemic injury,
in the Sgcd null mice. Although the differences in sever-necrosis, and fibrotic changes.
ity of the skeletal muscle phenotype could be related toTo confirm the hypothesis that the coronary artery
physiological differences between mouse and hamstervascular dysfunction initiates the development of myo-
species, another possibility would be that the type ofcardial ischemic-like lesions, we first subjected animals
the genetic lesion in each case has distinct influenceto treadmill exercise in order to induce stress and trigger
on the clinical phenotype. In respect to this, it is interest-the onset of cardiac muscle necrosis. Treadmill exercise
ing to note that recent genetic studies revealed expres-is one of the primary methods used clinically to induce
sion of d-sarcoglycan transcripts in some tissues of thecardiovascular stress in humans and animals (Fewell et
BIO 14.6 hamster (Sakamoto et al., 1999), suggestingal., 1997) and is used to detect cardiovascular abnormal-
that the BIO 14.6 hamster may not be completely defi-ities (e.g., coronary artery dysfunction) that may not be
cient in the d-sarcoglycan protein.readily apparent at rest. We chose young Sgcd null mice
A number of proteins with different subcellular local-at an age before cardiac muscle necrosis developed but
ization in cardiac muscle have been shown to be in-when vessel abnormalities were detected. Interestingly,
volved in cardiomyopathy. These proteins include theexercise-induced stress initiated the development of
cytoskeletal proteins actin (Olson et al., 1998) and des-multiple focal areas of myocardial ischemic-like lesions
min (Milner et al., 1996), as well as the muscle LIM proteinin the Sgcd null mice. Histological analysis of the myo-
(Arber et al., 1997) and the nuclear lamina protein lamincardial lesions displayed coagulation necrosis, which is
A/C (Bonne et al., 1999). These studies illustrate thata characteristic histological feature observed in condi-
different mechanisms at certain points in cardiac devel-tions associated with myocardial ischemia.
opment and in the adult heart involving the cytoskeletonSecond, in order to demonstrate that these observa-
and/or the nuclear lamina of the cardiac muscle cantions were related to vascular dysfunction, we treated
be implicated in the pathogenesis of cardiomyopathy.Sgcd null mice with Nicorandil, a vascular smooth mus-
However, our study opens up an important avenue ofcle relaxant compound. Nicorandil has been shown to
research directed toward the involvement of the vascu-relax coronary vascular smooth muscle by activation of
lar smooth muscle SG-SSPN complex in the pathogene-
potassium channels, resulting in hyperpolarization of
sis of cardiomyopathy.
the smooth muscle membrane, as well as by increasing
We are currently studying the molecular mechanism
cyclic GMP levels (Kukovetz et al., 1992). In addition, for the vascular dysfunctions observed in Sgcd null
Nicorandil has been shown to prevent coronary artery mice. Recent biochemical evidence suggests the pres-
vasospasms under a variety of conditions (Kaski, 1995). ence of at least three interconnected subcomplexesÐ
According to pharmacological studies, dilation of coro- dystrophin, dystroglycan, and sarcoglycanÐwithin the
nary artery microvessels depends on potassium channel DGC (Crosbie et al., 1999). The results indicate that the
activation and is mainly observed at low concentrations expression of each of these subcomplexes is a prerequi-
of Nicorandil (Kaski, 1995). We therefore applied Nicoran- site for the structural and functional membrane associa-
dil at a lower dose (1 mg/kg body weight intraperitone- tion of the DGC. It may be possible that the absence of
ally) to ensure that Nicorandil acted predominantly in the SG-SSPN complex leads to structural and/or confor-
the coronary artery microvasculature and did not lower mational changes of the remaining components of the
blood pressure. We have been able to successfully pre- DGC, which may be related to the abnormal contraction
vent mortality and the development of multiple myocar- and/or dilation of the vascular smooth muscle. Yet another
dial lesions in treadmill-stressed Sgcd null mice. In addi- possibility is that metabolic and signaling pathways are
tion, perfusion studies in Nicorandil-treated Sgcd null involved in the microvascular dysfunction. Elevated levels
mice showed the coronary microvascular bed free of of intracellular calcium, disturbances of the nitric oxide
constrictions and focal luminal narrowing. We cannot synthase pathway, as well as increased activity of protein
entirely rule out that the disruption of the SG-SSPN com- kinase C, have been implicated in increased contractility
and/or spasm of the microvasculature.plex and the loss of e-sarcoglycan in cardiac muscle of
Sarcoglycan±Sarcospan Complex and Cardiomyopathy
473
Creatine kinase values were determined in blood serum from wild-In summary, our study provides evidence for a novel
type and Sgcd null mice using the creatine kinase assay kit frommechanism in the pathogenesis of cardiomyopathy and
Sigma.muscular dystrophy. Disruption of the sarcoglycan±
sarcospan complex in vascular smooth muscle perturbs
Immunofluorescence Analysis
vascular function and induces ischemic injury in cardiac Hearts and skeletal muscle were isolated from wild-type, Sgca, and
and skeletal muscle. This mechanism provides a novel Sgcd null mice and rapidly frozen in liquid nitrogen±cooled isopen-
tane. Seven micrometer cryosections were prepared and analyzedinsight into the pathogenesis for these disorders. Thus,
by immunofluorescence using different antibodies as described pre-future genetic and pharmacological therapeutic ap-
viously (Duclos et al., 1998).proaches will need to be directed not only toward skele-
tal and cardiac muscle but also toward vascular smooth
Antibodies
muscle. Rabbit polyclonal antibodies against a-sarcoglycan (rabbit 98), dys-
trophin (rabbit 31), the laminin a2 chain, b-sarcoglycan (goat 26),
d-sarcoglycan N- and C-terminal peptide (rabbit 214 and 229, re-Experimental Procedures
spectively), and a-dystroglycan fusion protein D (goat 20) and
against b-dystroglycan C-terminal peptide (rabbit 83), sarcospan,Isolation of Mouse d-SG Genomic and cDNA Clones
and e-sarcoglycan (rabbit 235 and 232, respectively) were describedOne RT-PCR product from mouse skeletal muscle RNA was ob-
previously (Duclos et al., 1998). An affinity-purified rabbit polyclonaltained using the hamster primer HadFor5 (59-AGCTCAGAGGGGC
antibody was produced against a COOH-terminal fusion protein (aaCACAC-39, exon 2) and the mouse primer MdRev2 (59-CAGCCAGT
167±291) of g-sarcoglycan. A commercially available mouse mono-GTTTCAAGCCAA-39, exon 8). This product, containing exons 2±8
clonal antibody was used to detect smooth muscle actin (Sigma).of the d-sarcoglycan gene, was used to screen a Stratagene 129/
SV mouse genomic library in vector lFIXII (La Jolla, CA). Three
ECG Telemetrypositive clones were subcloned into pBlueScript KS (1) and restric-
Single-lead ECG recordings were performed in conscious, freelytion enzyme mapped using standard procedures.
mobile adult mice (3±4 months of age). Surgical anesthesia was
achieved with pentobarbital (30±40 mg/kg IP) with occasional expo-
Generation of Sgcd Null Mice
sure to inhaled methoxyflurane. Implantable radio transmitters (Data
The d-SG targeting vector was constructed using the positive-nega-
Sciences International, TA10EA-F20) were implanted in the subcuta-
tive selection vector pPNT. EcoRI and BamHI sites were introduced
neous tissues of the back. Two ECG leads were tunneled under the
by high-fidelity PCR mutagenesis (Takara enzyme) at the ends of a
skin to the ventral aspect of the thorax and sutured to the underlying
6 kb fragment that contains part of the d-SG intron 1 and exon 1b.
muscles (ECG lead II configuration). Serial recordings were made
The DNA was digested by EcoRI/BamHI and inserted in between
on the first three postoperative days.
the tk and neo genes of the vector. The second insert was obtained
by subcloning a 5 kb NotI±EcoRI d-SG intron 2 fragment into the
Microfil Perfusiondigested NotI±EcoRI pBlueScript. The insert was isolated by NotI±
In order to study coronary microvascular perfusion, mice were anes-XhoI digestion and cloned into the NotI and XhoI sites of the plasmid.
thetized with phenobarbital (75 mg/kg body weight), and a bilateralFollowing homologous recombination, a portion of intron 1, all of
sternum incision was performed to expose the left atrium. We per-exon 2, and part of intron 2 of the d-SG gene was replaced by the
fused 1±1.5 ml of Microfil, a liquid silicon rubber (Flow tech, Carver,neo gene (Figure 1). R1 ES cells were grown and electroporated
MA), into the left atrium. The heart continued beating for about 1with 10 mg of the NotI-linearized targeting plasmid. Colonies surviv-
min, and after contraction stopped, the heart was rapidly exciseding G418 and gancyclovir were isolated, expanded, and screened
and cured on ice for about 10 min. Adequacy of vascular perfusionby Southern blot (Figure 1). ES cell lines from two different correctly
was judged by the white blush that developed in the myocardiumtargeted clones were injected into C57BL/6J blastocysts and trans-
as well as the white filling of other main arteries (mesenteric arteryferred into pseudopregnant females. After germline transmission,
and femoral artery) of the mouse body. The heart was fixed in 10%DNA was extracted from the offsprings' tails, and the genotyping
formalin for 24 hr, and the next day the tissue was sliced into 2 mmwas done by PCR (Figure 1) using the following three different prim-
thick transverse cross sections and cleared by sequential 24 hrers in the same reaction: NeoTR (59-GCTATCAGGACATAGCGTTG
immersions in 25%, 50%, 75%, 95%, and finally 100% ethyl alcohol.GCTA-39); Mdint1F (59-GCAAACTTGGAGAGTGAAGAGGC-39); and
On day 6, specimens were placed in pure methyl salicylate for 12±24Mdint1R (59-GAGGCATATAAAG TTTGCACGAC-39).
hr. Microvascular perfusion was visualized with both epi- and transil-
lumination and examined under low-power magnification (310±20).
Northern Blot Analysis We quantified the vascular irregularities in Sgcd null mice at different
Total RNA was isolated from wild-type, d-SG (1/2), and d-SG (2/2) ages (2, 4, and 6 months) by counting the number of abnormal
skeletal muscle tissue using RNAzol B (Tel-Test) according to the individual vessel segments in ten nonadjacent microscopic fields
manufacturer's specifications. Twenty micrograms of the RNA was using a low magnification (103), and the mean number of abnormal
subjected to electrophoresis on a 1.25% agarose gel containing vessels was calculated for each mouse. An average number of ab-
5% formaldehyde, blotted to Hybond membrane (Amersham), and normal vessels 6 SEM was then calculated for each age group.
hybridized with either a 760 bp exon 2±8 probe or an exon 2 probe Vessel segments with more than one abnormality were only counted
from mouse d-SG cDNA. once.
Treadmill ExerciseHistopathology Studies
Wild-type mice (n 5 8), Sgca and Sgcd heterozygous (n 5 26), and Animals were exercised using the Omnipacer Treadmill Model LC4/
M-MGA/AT (Accuscan Instruments, Inc.), which had an adjustableSgcd null mice (n 5 26) were anesthetized with pentobarbital (0.75
mg/10 g of body weight) via intraperitoneal (IP) injection. Subse- belt speed (0±100 m/min), shock bars with adjustable amperage, and
an on-and-off shock switch for each lane. Animals were exercised atquently, the animals were perfused with PBS (15 ml) followed by 15
ml of 10% buffered formalin fixative solution. After embedding the 12±17 m/min for about 10 min and for 25±30 m/min for the remaining
40 min. If an animal became exhausted, the shock bar of this lanetissue in paraffin, H&E-stained sections (4 mm) were prepared in
order to characterize skeletal and cardiac muscle pathology. Some was turned off and the animal was allowed to rest at the back of
the treadmill for a short period of time. Wild-type (n 5 20), Sgca (n 5animals were sacrificed by cervical dislocation, and H&E staining
was performed on cryosections of skeletal and cardiac muscle. 20), and Sgcd null mice (n 5 42) were divided in approximately equal
numbers of males and females. All mice were injected with EvansFurthermore, H&E sections of brain, lung, liver, kidney, and spleen
were performed in some animals. No histopathology was observed blue dye (0.5 mg EBD/0.05 ml PBS) intraperitoneally 8 hr before the
exercise. Animals were injected with 50 ml of this solution per 10 gin these nonmuscle tissues.
Cell
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body weight. All surviving animals were kept alive for 36±48 hr, and for identifying cardiovascular phenotypes in transgenic mice. Am.
J. Physiol. 273, H1595±H1605.serial sections of cardiac muscle were studied for Evans blue uptake
and histopathological signs of necrosis by using routine H&E tech- Hack, A.A., Ly, C.T., Jiang, F., Clendenin, C.J., Sigrist, K.S., Woll-
nique. The effect of Nicorandil treatment on treadmill performance mann, R.L., and McNally, E.M. (1998). Gamma-sarcoglycan defi-
in wild-type (n 5 6), Sgca (n 5 6), and Sgcd null mice (n 5 20) was ciency leads to muscle membrane defects and apoptosis indepen-
studied after 3 days of intraperitoneal injection of Nicorandil at a dent of dystrophin. J. Cell Biol. 142, 1279±1287.
dose of 1 mg/kg body weight twice a day. Quantification of Evans Kaski, J.C. (1995). Management of vasospastic anginaÐrole of Ni-
blue positive stained areas in sections of cardiac muscle from Sgca corandil. Cardiovasc. Drugs Ther. 9, 221±227.
and Sgcd null mice (n 5 20, each group) was done by using the
Kukovetz, W.R., Holzmann, S., and Poech, G. (1992). MolecularScion image program. The percentage of positive stained areas was
mechanism of action of Nicorandil. J. Cardiovasc. Pharmacol. 20,calculated by dividing the area of staining by the total area of the
S1±S7.analyzed heart section.
Lim, L.E., and Campbell, K.P. (1998). The sarcoglycan complex in
limb-girdle muscular dystrophy. Curr. Opin. Neurol. 11, 443±452.
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